Trial NCT03992131

View at ClinicalTrials.gov 
Org. Study IDs: CO-338-098
Secondary IDs: 2018-003759-39

Last trial update was posted on 2024-01-16

MeSH Interventions

Rucaparib Sacituzumab govitecan

MeSH Conditions

Triple Negative Breast Neoplasms

Other Conditions

Ovarian Cancer Solid Tumor Triple-negative Breast Cancer Urothelial Carcinoma

Stopping Reasons

Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.

Limitations And Caveats

The study was terminated due to Sponsor's decision to discontinue development of the combination of rucaparib and sacituzumab govitecan.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID